Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

PURPOSE: This study aimed to determine activity and safety of weekly bortezomib and rituximab in patients with relapsed/refractory Waldenström macroglobulinemia (WM). PATIENTS AND METHODS: Patients who had at least one previous therapy were eligible. All patients received bortezomib intravenously we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ghobrial, Irene M., Hong, Fangxin, Padmanabhan, Swaminathan, Badros, Ashraf, Rourke, Meghan, Leduc, Renee, Chuma, Stacey, Kunsman, Janet, Warren, Diane, Harris, Brianna, Sam, Amy, Anderson, Kenneth C., Richardson, Paul G., Treon, Steven P., Weller, Edie, Matous, Jeffrey
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834499/
https://ncbi.nlm.nih.gov/pubmed/20142586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.3237
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados